Soligenix has been granted European Patent 1392321, "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The patent covers the use of topically active corticosteroids in orally-administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.
The dosage forms include orBec, an oral formulation of beclomethasone dipropionate (BDP), a topically active corticosteroid, currently in a confirmatory Phase 3 clinical trial for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), an inflammatory condition arising from hematopoietic stem cell transplantation.
Says Christopher Schaber, PhD, Soligenix President and CEO, "The patent demonstrates the novelty and utility of our approach to treating inflammatory GI diseases, such as GI GVHD with our two-pill system comprising an immediate- release and a delayed-release combination of oral BDP. We believe that our oral BDP formulations may also have utility in other inflammatory GI diseases, such as radiation enteritis, irritable bowel syndrome and Crohn's disease."
- check out the Soligenix release